NR 566 Week 1 Exam: Questions & Answers( Update)
Advanced Pharmacology - Care of the Family | Chamberlain
University - 200 Questions
This exam assesses advanced understanding of pharmacokinetic and pharmacodynamic principles, including
absorption, distribution, metabolism, excretion, receptor theory, dose-response relationships, and clinical
application. Questions require integration of physiological, biochemical, and pharmacological concepts at a level
appropriate for doctoral-level nursing practice. It contains 200 multiple-choice questions, each with four
distractors and a fully worked rationale that explains why the keyed answer is correct. Content is organized into
10 focused sections: Pharmacokinetics and Pharmacodynamics, Autonomic Nervous System Drugs,
Cardiovascular Pharmacology, Respiratory Pharmacology, Endocrine Pharmacology, Central Nervous System
Drugs, Antimicrobial Therapy, Pain Management and Analgesics, Women's Health and Reproductive
Pharmacology, Pediatric and Geriatric Pharmacology Considerations. Targeted learning outcomes include:
Analyze the impact of physiological changes on drug absorption, distribution, metabolism, and excretion.;
Evaluate pharmacodynamic concepts including receptor binding, efficacy, potency, and therapeutic index.; Apply
pharmacokinetic principles to optimize drug dosing in special populations.; Interpret dose-response curves and
predict clinical outcomes based on pharmacokinetic parameters.. Every item has been reviewed for clinical
accuracy, current guidelines, and clarity so that students can study with confidence and self-correct as they work
through the bank. Use it as a high-yield review immediately before the exam, or as a structured practice tool
Section 1: Pharmacokinetics and Pharmacodynamics (Questions 1-20)
1 A drug exhibits a volume of distribution (Vd) of 500 L and a clearance (Cl) of 50 L/hr. Assuming first-order
elimination, what is the elimination half-life (t½) of this drug?
A) 3.5 hours
B) 5.0 hours
C) 6.9 hours
D) 10.0 hours
Answer: C
Rationale: Half-life is calculated as t½ = 0.693 × Vd / Cl. Here, t½ = 0.693 × = 6.93 hours, approximately
6.9 hours. Option A (3.5 hours) results from using Vd/Cl without 0.693; Option B uses incorrect formula; Option D
assumes t½ = Vd/Cl.
2 A drug with a narrow therapeutic index is administered orally. Which of the following scenarios would most
likely result in a subtherapeutic response if the drug follows first-order kinetics and has high first-pass
metabolism?
A) Concomitant administration with a drug that induces CYP3A4
B) Administration with a high-fat meal that increases gastric emptying
C) Chronic use of a proton pump inhibitor that raises gastric pH
D) Co-administration with a drug that inhibits P-glycoprotein in the gut
Answer: A
Rationale: Induction of CYP3A4 increases first-pass metabolism, reducing bioavailability and potentially leading to
subtherapeutic levels. Option B (high-fat meal) may increase absorption of lipophilic drugs but not necessarily
subtherapeutic. Option C (PPI) could alter absorption of pH-dependent drugs but not consistently. Option D (P-gp
inhibition) typically increases absorption, not decreases.
,3 A patient with chronic kidney disease (CKD) stage 4 is prescribed a drug that is primarily eliminated unchanged
by the kidneys. Which of the following pharmacokinetic parameters is most likely to be significantly altered,
requiring dose adjustment?
A) Bioavailability
B) Volume of distribution
C) Clearance
D) Peak concentration (Cmax)
Answer: C
Rationale: Renal clearance is directly affected by kidney function; in CKD, clearance decreases, prolonging half-life
and requiring dose reduction. Bioavailability (A) is not primarily affected by renal function. Volume of distribution
(B) may change due to fluid shifts but not as directly. Peak concentration (D) depends on dose and absorption rate,
not primarily on elimination.
4 Two drugs, X and Y, are both agonists at the same receptor. Drug X produces a maximal response at 10 mg,
while Drug Y requires 100 mg to achieve the same maximal response. However, Drug Y has a higher maximal
efficacy. Which of the following statements is correct?
A) Drug X is more potent and has higher efficacy than Drug Y
B) Drug X is more potent, but Drug Y has higher efficacy
C) Drug Y is more potent and has higher efficacy than Drug X
D) Drug Y is more potent, but Drug X has higher efficacy
Answer: B
Rationale: Potency refers to the dose required to produce a given effect; Drug X achieves maximal response at lower
dose, so it is more potent. Efficacy is the maximum effect achievable; Drug Y has higher maximal efficacy. Thus,
X is more potent, Y has higher efficacy. Options A, C, D incorrectly assign potency or efficacy.
5 A drug follows a two-compartment pharmacokinetic model. After an intravenous bolus dose, the plasma
concentration-time curve shows a rapid initial decline followed by a slower terminal phase. Which of the
following best explains the initial rapid decline?
A) Rapid metabolism by hepatic enzymes
B) Distribution from central compartment to peripheral tissues
C) Elimination via renal filtration
D) Binding to plasma proteins reducing free drug concentration
Answer: B
Rationale: In a two-compartment model, the initial rapid decline (alpha phase) is due to distribution of drug from the
central compartment (blood) to peripheral tissues. Metabolism (A) and elimination (C) contribute to the terminal
phase. Protein binding (D) affects distribution but is not the primary cause of the rapid decline.
6 Which of the following best describes the relationship between the therapeutic index (TI) and the margin of
safety of a drug?
A) A high TI indicates a narrow margin of safety
B) TI is calculated as TD50/ED50, and a larger ratio indicates a wider margin of safety
C) TI is calculated as LD50/ED50, and a smaller ratio indicates a wider margin of safety
D) TI is irrelevant to clinical safety; only the therapeutic window matters
Answer: B
Rationale: The therapeutic index is typically defined as TD50/ED50 (or LD50/ED50). A larger ratio means the toxic
dose is much higher than the effective dose, indicating a wider margin of safety. Option A is opposite; Option C
incorrectly states smaller ratio indicates wider safety; Option D ignores that TI is a key safety measure.
, 7 A drug is a weak acid with pKa 4.5. In which of the following compartments would the drug be most highly
ionized?
A) Gastric fluid (pH 1.5)
B) Duodenal fluid (pH 6.0)
C) Blood plasma (pH 7.4)
D) Urine (pH 5.0)
Answer: C
Rationale: For a weak acid, ionization increases as pH increases above pKa. At pH 7.4 (plasma), pH > pKa, so the
drug is predominantly ionized. At pH 1.5 (gastric), pH < pKa, drug is unionized. At pH 6.0 and 5.0, partial
ionization occurs but less than at pH 7.4. Thus, option C is correct.
8 A patient is receiving a drug that is a substrate of CYP2D6. The patient is also taking a potent CYP2D6
inhibitor. Which of the following changes is most likely to occur in the pharmacokinetics of the substrate drug?
A) Decreased area under the curve (AUC)
B) Increased clearance
C) Increased half-life
D) Decreased peak concentration (Cmax)
Answer: C
Rationale: Inhibition of CYP2D6 reduces metabolism of the substrate, leading to decreased clearance, increased
AUC, increased half-life, and potentially increased Cmax. Option A (decreased AUC) is opposite; Option B
(increased clearance) is opposite; Option D (decreased Cmax) is not typical unless absorption is affected.
9 A drug has a bioavailability of 0.8 and is administered orally at a dose of 100 mg. The apparent volume of
distribution is 50 L. Assuming complete absorption and first-order elimination, what is the approximate initial
plasma concentration (C0) after a single oral dose?
A) 0.8 mg/L
B) 1.6 mg/L
C) 2.0 mg/L
D) 4.0 mg/L
Answer: B
Rationale: C0 = (F × Dose) / Vd = (0.8 × 100 mg) / 50 L = 80 mg / 50 L = 1.6 mg/L. Option A (0.8) results from
using F without dose; Option C (2.0) uses dose 100/50 ignoring F; Option D (4.0) uses dose 200/50.
10 Which of the following best describes the concept of 'intrinsic activity' in pharmacodynamics?
A) The ability of a drug to bind to a receptor
B) The maximum effect a drug can produce when occupying all receptors
C) The dose required to produce 50% of the maximal effect
D) The rate at which a drug dissociates from the receptor
Answer: B
Rationale: Intrinsic activity (efficacy) is the ability of a drug to activate a receptor and produce a response; it is the
maximum effect achievable. Option A describes affinity; Option C describes potency (ED50); Option D describes
dissociation rate constant.
11 A drug exhibits a volume of distribution (Vd) of 500 L and a clearance (Cl) of 50 L/h. After a single
intravenous bolus dose, what is the approximate elimination half-life?
A) 3.5 hours
B) 6.9 hours
, C) 10 hours
D) 14 hours
Answer: B
Rationale: Half-life (t1/2) = 0.693 × Vd / Cl = 0.693 × 500 L / 50 L/h = 6.93 hours. Option A (3.5 h) would require
Vd of 250 L; Option C (10 h) would require Cl of 35 L/h; Option D (14 h) would require Cl of 25 L/h.
12 A drug follows a two-compartment pharmacokinetic model. After IV bolus, the plasma concentration-time
curve shows a rapid initial decline followed by a slower terminal phase. Which parameter best describes the
initial rapid decline?
A) Distribution half-life
B) Elimination half-life
C) Volume of distribution at steady state
D) Clearance
Answer: A
Rationale: In a two-compartment model, the initial rapid decline is due to distribution from central to peripheral
compartment, characterized by distribution half-life. Elimination half-life (B) describes the terminal phase. Volume
of distribution (C) and clearance (D) are overall parameters, not specific to the initial phase.
13 A patient with severe hepatic impairment is prescribed a drug that undergoes extensive first-pass metabolism.
Which pharmacokinetic parameter is most likely altered, and what is the expected change?
A) Increased bioavailability due to reduced hepatic extraction
B) Decreased half-life due to increased volume of distribution
C) Increased clearance due to enzyme induction
D) Decreased bioavailability due to increased protein binding
Answer: A
Rationale: First-pass metabolism reduces bioavailability. In hepatic impairment, hepatic extraction is reduced,
leading to increased bioavailability (A). Half-life (B) is more likely increased due to decreased clearance. Clearance
(C) is decreased, not increased. Protein binding (D) may affect distribution but not directly decrease bioavailability.
14 Two drugs, A and B, are both highly protein bound (>95%) and are administered concurrently. Drug A has a
higher affinity for albumin than drug B. Which of the following is the most likely consequence?
A) Increased free fraction of drug B, potentially leading to toxicity
B) Decreased free fraction of drug A, reducing its efficacy
C) Increased clearance of drug A due to displacement
D) No change in free concentrations of either drug
Answer: A
Rationale: Displacement from protein binding sites increases free fraction of the displaced drug (B). Drug A, with
higher affinity, displaces B, increasing B's free concentration and risk of toxicity (A). Drug A's free fraction may
decrease slightly but not enough to reduce efficacy (B). Clearance (C) may increase for B, not A. Option D is
incorrect because displacement occurs.
15 A drug has a narrow therapeutic index and is eliminated primarily by renal excretion. A patient with chronic
kidney disease (CKD) stage 4 (eGFR 20 mL/min) requires this drug. Which dosing adjustment is most
appropriate?
A) Increase dose and lengthen dosing interval
B) Decrease dose and maintain dosing interval
C) Maintain dose and shorten dosing interval
Advanced Pharmacology - Care of the Family | Chamberlain
University - 200 Questions
This exam assesses advanced understanding of pharmacokinetic and pharmacodynamic principles, including
absorption, distribution, metabolism, excretion, receptor theory, dose-response relationships, and clinical
application. Questions require integration of physiological, biochemical, and pharmacological concepts at a level
appropriate for doctoral-level nursing practice. It contains 200 multiple-choice questions, each with four
distractors and a fully worked rationale that explains why the keyed answer is correct. Content is organized into
10 focused sections: Pharmacokinetics and Pharmacodynamics, Autonomic Nervous System Drugs,
Cardiovascular Pharmacology, Respiratory Pharmacology, Endocrine Pharmacology, Central Nervous System
Drugs, Antimicrobial Therapy, Pain Management and Analgesics, Women's Health and Reproductive
Pharmacology, Pediatric and Geriatric Pharmacology Considerations. Targeted learning outcomes include:
Analyze the impact of physiological changes on drug absorption, distribution, metabolism, and excretion.;
Evaluate pharmacodynamic concepts including receptor binding, efficacy, potency, and therapeutic index.; Apply
pharmacokinetic principles to optimize drug dosing in special populations.; Interpret dose-response curves and
predict clinical outcomes based on pharmacokinetic parameters.. Every item has been reviewed for clinical
accuracy, current guidelines, and clarity so that students can study with confidence and self-correct as they work
through the bank. Use it as a high-yield review immediately before the exam, or as a structured practice tool
Section 1: Pharmacokinetics and Pharmacodynamics (Questions 1-20)
1 A drug exhibits a volume of distribution (Vd) of 500 L and a clearance (Cl) of 50 L/hr. Assuming first-order
elimination, what is the elimination half-life (t½) of this drug?
A) 3.5 hours
B) 5.0 hours
C) 6.9 hours
D) 10.0 hours
Answer: C
Rationale: Half-life is calculated as t½ = 0.693 × Vd / Cl. Here, t½ = 0.693 × = 6.93 hours, approximately
6.9 hours. Option A (3.5 hours) results from using Vd/Cl without 0.693; Option B uses incorrect formula; Option D
assumes t½ = Vd/Cl.
2 A drug with a narrow therapeutic index is administered orally. Which of the following scenarios would most
likely result in a subtherapeutic response if the drug follows first-order kinetics and has high first-pass
metabolism?
A) Concomitant administration with a drug that induces CYP3A4
B) Administration with a high-fat meal that increases gastric emptying
C) Chronic use of a proton pump inhibitor that raises gastric pH
D) Co-administration with a drug that inhibits P-glycoprotein in the gut
Answer: A
Rationale: Induction of CYP3A4 increases first-pass metabolism, reducing bioavailability and potentially leading to
subtherapeutic levels. Option B (high-fat meal) may increase absorption of lipophilic drugs but not necessarily
subtherapeutic. Option C (PPI) could alter absorption of pH-dependent drugs but not consistently. Option D (P-gp
inhibition) typically increases absorption, not decreases.
,3 A patient with chronic kidney disease (CKD) stage 4 is prescribed a drug that is primarily eliminated unchanged
by the kidneys. Which of the following pharmacokinetic parameters is most likely to be significantly altered,
requiring dose adjustment?
A) Bioavailability
B) Volume of distribution
C) Clearance
D) Peak concentration (Cmax)
Answer: C
Rationale: Renal clearance is directly affected by kidney function; in CKD, clearance decreases, prolonging half-life
and requiring dose reduction. Bioavailability (A) is not primarily affected by renal function. Volume of distribution
(B) may change due to fluid shifts but not as directly. Peak concentration (D) depends on dose and absorption rate,
not primarily on elimination.
4 Two drugs, X and Y, are both agonists at the same receptor. Drug X produces a maximal response at 10 mg,
while Drug Y requires 100 mg to achieve the same maximal response. However, Drug Y has a higher maximal
efficacy. Which of the following statements is correct?
A) Drug X is more potent and has higher efficacy than Drug Y
B) Drug X is more potent, but Drug Y has higher efficacy
C) Drug Y is more potent and has higher efficacy than Drug X
D) Drug Y is more potent, but Drug X has higher efficacy
Answer: B
Rationale: Potency refers to the dose required to produce a given effect; Drug X achieves maximal response at lower
dose, so it is more potent. Efficacy is the maximum effect achievable; Drug Y has higher maximal efficacy. Thus,
X is more potent, Y has higher efficacy. Options A, C, D incorrectly assign potency or efficacy.
5 A drug follows a two-compartment pharmacokinetic model. After an intravenous bolus dose, the plasma
concentration-time curve shows a rapid initial decline followed by a slower terminal phase. Which of the
following best explains the initial rapid decline?
A) Rapid metabolism by hepatic enzymes
B) Distribution from central compartment to peripheral tissues
C) Elimination via renal filtration
D) Binding to plasma proteins reducing free drug concentration
Answer: B
Rationale: In a two-compartment model, the initial rapid decline (alpha phase) is due to distribution of drug from the
central compartment (blood) to peripheral tissues. Metabolism (A) and elimination (C) contribute to the terminal
phase. Protein binding (D) affects distribution but is not the primary cause of the rapid decline.
6 Which of the following best describes the relationship between the therapeutic index (TI) and the margin of
safety of a drug?
A) A high TI indicates a narrow margin of safety
B) TI is calculated as TD50/ED50, and a larger ratio indicates a wider margin of safety
C) TI is calculated as LD50/ED50, and a smaller ratio indicates a wider margin of safety
D) TI is irrelevant to clinical safety; only the therapeutic window matters
Answer: B
Rationale: The therapeutic index is typically defined as TD50/ED50 (or LD50/ED50). A larger ratio means the toxic
dose is much higher than the effective dose, indicating a wider margin of safety. Option A is opposite; Option C
incorrectly states smaller ratio indicates wider safety; Option D ignores that TI is a key safety measure.
, 7 A drug is a weak acid with pKa 4.5. In which of the following compartments would the drug be most highly
ionized?
A) Gastric fluid (pH 1.5)
B) Duodenal fluid (pH 6.0)
C) Blood plasma (pH 7.4)
D) Urine (pH 5.0)
Answer: C
Rationale: For a weak acid, ionization increases as pH increases above pKa. At pH 7.4 (plasma), pH > pKa, so the
drug is predominantly ionized. At pH 1.5 (gastric), pH < pKa, drug is unionized. At pH 6.0 and 5.0, partial
ionization occurs but less than at pH 7.4. Thus, option C is correct.
8 A patient is receiving a drug that is a substrate of CYP2D6. The patient is also taking a potent CYP2D6
inhibitor. Which of the following changes is most likely to occur in the pharmacokinetics of the substrate drug?
A) Decreased area under the curve (AUC)
B) Increased clearance
C) Increased half-life
D) Decreased peak concentration (Cmax)
Answer: C
Rationale: Inhibition of CYP2D6 reduces metabolism of the substrate, leading to decreased clearance, increased
AUC, increased half-life, and potentially increased Cmax. Option A (decreased AUC) is opposite; Option B
(increased clearance) is opposite; Option D (decreased Cmax) is not typical unless absorption is affected.
9 A drug has a bioavailability of 0.8 and is administered orally at a dose of 100 mg. The apparent volume of
distribution is 50 L. Assuming complete absorption and first-order elimination, what is the approximate initial
plasma concentration (C0) after a single oral dose?
A) 0.8 mg/L
B) 1.6 mg/L
C) 2.0 mg/L
D) 4.0 mg/L
Answer: B
Rationale: C0 = (F × Dose) / Vd = (0.8 × 100 mg) / 50 L = 80 mg / 50 L = 1.6 mg/L. Option A (0.8) results from
using F without dose; Option C (2.0) uses dose 100/50 ignoring F; Option D (4.0) uses dose 200/50.
10 Which of the following best describes the concept of 'intrinsic activity' in pharmacodynamics?
A) The ability of a drug to bind to a receptor
B) The maximum effect a drug can produce when occupying all receptors
C) The dose required to produce 50% of the maximal effect
D) The rate at which a drug dissociates from the receptor
Answer: B
Rationale: Intrinsic activity (efficacy) is the ability of a drug to activate a receptor and produce a response; it is the
maximum effect achievable. Option A describes affinity; Option C describes potency (ED50); Option D describes
dissociation rate constant.
11 A drug exhibits a volume of distribution (Vd) of 500 L and a clearance (Cl) of 50 L/h. After a single
intravenous bolus dose, what is the approximate elimination half-life?
A) 3.5 hours
B) 6.9 hours
, C) 10 hours
D) 14 hours
Answer: B
Rationale: Half-life (t1/2) = 0.693 × Vd / Cl = 0.693 × 500 L / 50 L/h = 6.93 hours. Option A (3.5 h) would require
Vd of 250 L; Option C (10 h) would require Cl of 35 L/h; Option D (14 h) would require Cl of 25 L/h.
12 A drug follows a two-compartment pharmacokinetic model. After IV bolus, the plasma concentration-time
curve shows a rapid initial decline followed by a slower terminal phase. Which parameter best describes the
initial rapid decline?
A) Distribution half-life
B) Elimination half-life
C) Volume of distribution at steady state
D) Clearance
Answer: A
Rationale: In a two-compartment model, the initial rapid decline is due to distribution from central to peripheral
compartment, characterized by distribution half-life. Elimination half-life (B) describes the terminal phase. Volume
of distribution (C) and clearance (D) are overall parameters, not specific to the initial phase.
13 A patient with severe hepatic impairment is prescribed a drug that undergoes extensive first-pass metabolism.
Which pharmacokinetic parameter is most likely altered, and what is the expected change?
A) Increased bioavailability due to reduced hepatic extraction
B) Decreased half-life due to increased volume of distribution
C) Increased clearance due to enzyme induction
D) Decreased bioavailability due to increased protein binding
Answer: A
Rationale: First-pass metabolism reduces bioavailability. In hepatic impairment, hepatic extraction is reduced,
leading to increased bioavailability (A). Half-life (B) is more likely increased due to decreased clearance. Clearance
(C) is decreased, not increased. Protein binding (D) may affect distribution but not directly decrease bioavailability.
14 Two drugs, A and B, are both highly protein bound (>95%) and are administered concurrently. Drug A has a
higher affinity for albumin than drug B. Which of the following is the most likely consequence?
A) Increased free fraction of drug B, potentially leading to toxicity
B) Decreased free fraction of drug A, reducing its efficacy
C) Increased clearance of drug A due to displacement
D) No change in free concentrations of either drug
Answer: A
Rationale: Displacement from protein binding sites increases free fraction of the displaced drug (B). Drug A, with
higher affinity, displaces B, increasing B's free concentration and risk of toxicity (A). Drug A's free fraction may
decrease slightly but not enough to reduce efficacy (B). Clearance (C) may increase for B, not A. Option D is
incorrect because displacement occurs.
15 A drug has a narrow therapeutic index and is eliminated primarily by renal excretion. A patient with chronic
kidney disease (CKD) stage 4 (eGFR 20 mL/min) requires this drug. Which dosing adjustment is most
appropriate?
A) Increase dose and lengthen dosing interval
B) Decrease dose and maintain dosing interval
C) Maintain dose and shorten dosing interval
